中集安瑞科(03899.HK)氫能合資公司獲澳洲車載供氫系統訂單
中集安瑞科(03899.HK)公布,中集安瑞科與Hexagon Purus的氫能合資公司「中集合斯康」成功獲得首個70Mpa IV型車載供氫系統出口澳洲訂單,為公司首個出口的70Mpa IV型車載供氫系統產品,將運用在客戶于澳洲運行的氫能重卡,料為公司拓展澳大利亞氫能重卡市場奠定良好基礎。
目前中集安瑞科所生產的35Mpa III型車載瓶及供氫系統,已批量應用於氫燃料電池叉車、重卡及巴士等領域,而IV型車載瓶及供氫系統目前已在香港銷售。中集安瑞科副總經理兼氫能業務中心負責人楊葆英表示,未來將繼續與行業夥伴合作,推動IV型瓶及供氫系統於海內外的規模化應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.